Stock Market & Financial Investment News

News Breaks February 14, 2013 17:56 EDT CVS, MDT Relational Investors reports decreased stakes in CVS Caremark, Medtronic News For CVS;MDT From The Last 14 Days Check below for free stories on CVS;MDT the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 09:04 EDT MDT Wells Faro to host a conference 2013 Healthcare Conference is being held in Boston on June 18-19 with webcasted company presentations to begin at 8:15 am; not all company presentations may be webcasted. Webcast Link 07:56 EDT MDT Medtronic InFuse sales unlikely to drop meaningfully, says Stifel After examining Yale's review of Medtronic's InFuse program, Stifel doesn't see any significant surprises in the report that would trigger a meaningful downturn in sales of the product. The firm keeps a Hold rating on Medtronic. 07:28 EDT MDT Wells Faro to host a conference Subscribe for More Information 07:22 EDT MDT Impact to Medtronic from Infuse risk manageable, says Bernstein After Yale reviewed Medtronic's Infuse product and found that it slightly increases cancer risk, Bernstein expects the impact on Medtronic's stock to be manageable, as Infuse makes up only 3% of the company's sales and less of its profits. The firm expects Infuse sales to drop by about 4% in FY14, but it keeps an Outperform rating on the stock. June 17, 2013 18:02 EDT MDT Medtronic acknowledges findings from Yale review of Infuse bone graft Subscribe for More Information June 14, 2013 09:57 EDT MDT Court ruling a minor negative for Edwards Lifesciences, says Leerink Subscribe for More Information 09:45 EDT MDT Edwards lost first of three cases against Medtronic, says Wells Fargo Subscribe for More Information 07:53 EDT MDT Edwards loses patent bid in Germany versus Medtronic, Bloomberg says A German court ruled that Edwards Lifescience's (EW) patent does not cover Medtronic's (MDT) product, Bloomberg reports. June 13, 2013 11:02 EDT MDT Leerink's major pharma analyst holds an analyst/Industry conference call Subscribe for More Information 05:17 EDT MDT Medtronic announce CE Mark of ReDux Plier instrument Subscribe for More Information June 12, 2013 14:55 EDT CVS CVS Caremark management to meet with Lazard Capital Subscribe for More Information 07:08 EDT CVS Drugstores ready access changes to Plan B pill, WSJ reports Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, reports the Wall Street Journal.Reference Link 06:05 EDT CVS On the Fly: Periodicals Wrap-Up WALL STREET JOURNAL: The tectonic plates of the world economy are shifting, moving the yield on the 10-year Treasury to the highest level in more than a year and shaking financial markets. Now, some constants are being questioned in markets, triggering paroxysms in stocks, bonds, commodities and the currencies of emerging markets, the Wall Street Journal reports...Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, the Wall Street Journal reports...REUTERS: If currency turbulence in emerging markets becomes a full-scale investor flight, the Fed may have a new headache in deciding when to slow its dollar printing policy. The link between U.S. monetary policy and currency runs on the other side of the world could be tighter than many assume, Reuters reports...Toyota Motor (TM) said it’s unlikely to recapture its peak market share it held four years ago in the U.S. (GM, F), its biggest market, the latest sign the carmaker is shifting to improving quality from aggressively expanding sales, Reuters reports...BLOOMBERG: Exchange executives (NYX, NDAQ), long shielded from legal scrutiny in the U.S., have been put on notice that may be changing after federal regulators fined CBOE Holdings (CBOE) $6M for unprecedented lapses in supervision, Bloomberg reports...Borealis Infrastructure Management and its Kuwaiti-British partners abandoned their $8.3B bid for the U.K. water utility Severn Trent (SVTRY) as the offer deadline expired, Bloomberg reports. 05:25 EDT MDT NuVasive announces court ruling, intends to appeal verdict in Medtronic case NuVasive announced that it received a ruling from the U.S. District Court in regards to ongoing royalty rates for Phase I of its patent litigation with Medtronic. As part of the verdict in Phase I of the litigation, royalty rates were determined by the jury as follows: 10% on certain of NuVasive's CoRoent XL implants and 3% on certain MaXcess retractors and related products. Before the appeal in Phase I could move forward, the Court was required to determine the ongoing royalty rates applicable to these products during the period of time following the verdict. Medtronic requested ongoing royalty rates of 36% on the applicable NuVasive CoRoent XL implants and 11% on the applicable MaXcess retractors and related products. However, in the ruling received, the Court ordered royalty rates of 13.75% on the applicable CoRoent XL implants and 8.25% on the applicable MaXcess retractors. Since September 2011, NuVasive has been accruing an estimated litigation royalty expense based on the royalty rates used in the jury's original calculation of lost profits and monetary damages. Prior to the post-verdict rates issued by the Court, the company had expected litigation royalty expense of approximately $11M for FY13. The new royalty rates determined today will increase that expected litigation royalty expense for 2013 by approximately $5M. In addition, in the current quarter, the company will record an approximate $6.5M charge to account for the historical difference between the post-verdict royalty rates determined today and the rates that were being used to calculate the litigation royalty expense accruals since September 2011. The vast majority of the litigation royalty expense accruals will end in February 2015 as certain Medtronic patents expire. As the verdict is being appealed, the company will accrue to the higher rates determined and will begin to escrow funds on a go-forward basis. June 11, 2013 08:32 EDT CVS CVS Caremark receives URAC accerditation in specialty pharmacy CVS Caremark announced that it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry. June 10, 2013 07:20 EDT MDT Biomed to host a conference Subscribe for More Information 07:19 EDT MDT PTC to host conference Subscribe for More Information June 7, 2013 11:57 EDT CVS Leerink's healthcare technology & distribution analyst holds a conference call Subscribe for More Information 08:23 EDT MDT Medtronic has a conference call hosted by JPMorgan Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.